Drug intelligence / Profile preview

CBL8851

Development stage: Phase 1
Lead developer: Changchun BCHT Biotechnology
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intramuscular

Overview

CBL8851 is an investigational fixed-combination formulation of two fully human monoclonal antibodies, A82 and B86, directed against tetanus toxin. Developed by Changchun BCHT for passive tetanus prophylaxis, the antibody pair is intended to neutralize tetanus toxin through dual-epitope targeting, providing an alternative to plasma-derived human tetanus immunoglobulin. It is being evaluated by intramuscular injection in Phase I/II clinical studies in healthy adults, including comparison with human tetanus immunoglobulin and co-administration studies with tetanus vaccine. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06360250))

Other names: A82/B86A82/B86 injection combination formulationFully human anti-tetanus toxin monoclonal antibody A82/B86

Beyond the preview

Go deeper on CBL8851.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CBL8851.

Explore the full profile